Investor List:

Top Pharmaceuticals Series A Investors in London (33)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Pharmaceuticals investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Alessandro Luciano, Vice President at Insight Partners
Alessandro Luciano
Insight Partners·Vice President
Sweet spot: $25.0M
Range: $10.0M - $350.0M
Investors in London
Photo of Pablo Lubroth, Investor at Hummingbird Ventures
Pablo Lubroth
Sweet spot: $2.8M
Range: $500K - $5.0M
Investors in London, Investors in New York (NY)
Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in DeepTech (Seed), Investors in Digital Health (Seed), Investors in Therapeutics (Seed), Investors in DeepTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in DeepTech (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Therapeutics (Series A), Investors in DeepTech (Series A), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in DeepTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Pharmaceuticals (Series A), Investors in DeepTech (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series B), Investors in DeepTech (Series B), Investors in Therapeutics (Series B), Investors in DeepTech (Series B), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Pharmaceuticals (Series B), Investors in DeepTech (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in London (Other Lists), Investors in New York City (Other Lists)
Photo of Hussein Kanji, Analyst at Hoxton Ventures
Hussein Kanji
Sweet spot: $2.0M
Range: $1M - $3.0M
Investors in United Kingdom, Investors in London
Investors in Pharmaceuticals (Pre-seed), Investors in Retail (Pre-seed), Investors in AI (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Analytics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Security (Pre-seed), Investors in Consumer Internet (Pre-seed), Investors in Marketplaces (Pre-seed), Investors in SaaS (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Retail (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Security (Pre-seed), Investors in Digital Health (Pre-seed), Investors in AI (Pre-seed), Investors in Analytics (Pre-seed), Investors in Marketplaces (Pre-seed), Investors in Consumer Internet (Pre-seed), Investors in SaaS (Pre-seed), Investors in Pharmaceuticals (Seed), Investors in AI (Seed), Investors in Analytics (Seed), Investors in Digital Health (Seed), Investors in Retail (Seed), Investors in Security (Seed), Investors in Enterprise Applications (Seed), Investors in Marketplaces (Seed), Investors in Consumer Internet (Seed), Investors in SaaS (Seed), Investors in Pharmaceuticals (Seed), Investors in Retail (Seed), Investors in Security (Seed), Investors in Enterprise Applications (Seed), Investors in AI (Seed), Investors in Analytics (Seed), Investors in Digital Health (Seed), Investors in Marketplaces (Seed), Investors in Consumer Internet (Seed), Investors in SaaS (Seed), Investors in Pharmaceuticals (Series A), Investors in AI (Series A), Investors in Analytics (Series A), Investors in Digital Health (Series A), Investors in Enterprise Applications (Series A), Investors in Security (Series A), Investors in Retail (Series A), Investors in Marketplaces (Series A), Investors in SaaS (Series A), Investors in Consumer Internet (Series A), Investors in Pharmaceuticals (Series A), Investors in Retail (Series A), Investors in Security (Series A), Investors in Enterprise Applications (Series A), Investors in Analytics (Series A), Investors in AI (Series A), Investors in Digital Health (Series A), Investors in Marketplaces (Series A), Investors in SaaS (Series A), Investors in Consumer Internet (Series A), Investors in Diverse Investors (Other Lists), Investors in London (Other Lists), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists)
Photo of Bali Muralidhar, Managing Partner at Abingworth
Bali Muralidhar
Abingworth·Managing Partner
Sweet spot: $22.5M
Range: $15.0M - $30.0M
Investors in London
Photo of Andrew Kozlov, Managing Partner at 4BIO Capital
Andrew Kozlov
4BIO Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in London (Other Lists)
Photo of Shahzad Malik, General Partner at Advent Life Sciences
Shahzad Malik
Advent Life Sciences·General Partner
Sweet spot: $1M
Range: $25K - $5.0M
Investors in London
Photo of Robert Thong, General Partner at Selvedge Venture
Robert Thong
Selvedge Venture·General Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in Pharmaceuticals (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health IT (Pre-seed), Investors in Enterprise (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health IT (Pre-seed), Investors in Enterprise (Pre-seed), Investors in Pharmaceuticals (Seed), Investors in Enterprise Applications (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in Enterprise (Seed), Investors in Pharmaceuticals (Seed), Investors in Enterprise Applications (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Enterprise (Seed), Investors in Pharmaceuticals (Series A), Investors in Enterprise Applications (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Enterprise (Series A), Investors in Pharmaceuticals (Series A), Investors in Enterprise Applications (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Enterprise (Series A), Investors in London (Other Lists)
Photo of Shu Joshi, Managing Partner at Life Science Vision (LSV) Capital
Shu Joshi
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London